How long you can live with stomach cancer depends heavily on when it’s found. When the cancer is still confined to the stomach, the five-year survival rate is about 75 to 78%. Once it has spread to distant organs, that number drops to around 7 to 8%. Between those extremes, the range is wide, and several factors beyond stage play a meaningful role in individual outcomes.
These are population-level statistics, meaning they reflect averages across thousands of people diagnosed over the past several years. They don’t predict what will happen to any one person, but they give a realistic framework for understanding what to expect.
Survival Rates by Stage
Stage at diagnosis is the single biggest factor in stomach cancer survival. Data from the National Cancer Institute’s SEER database breaks it down into three categories based on how far the cancer has spread:
- Localized (still in the stomach only): 78.1% five-year survival
- Regional (spread to nearby lymph nodes or tissue): 39.0% five-year survival
- Distant (spread to other organs): 8.1% five-year survival
These are relative survival rates, which means they compare people with stomach cancer to the general population of the same age. A 78% relative survival rate doesn’t mean 22% of people with localized cancer die from it. Some of those deaths are from unrelated causes. The numbers isolate the effect of the cancer itself as closely as possible.
Unfortunately, stomach cancer is often caught late because early symptoms (mild indigestion, bloating, loss of appetite) overlap with many common, harmless conditions. By the time pain, unintended weight loss, or difficulty swallowing prompt a visit to the doctor, the cancer may have already moved beyond the stomach wall.
Stage IV: What the Numbers Show
For people diagnosed with stage IV stomach cancer, meaning the disease has metastasized to distant sites like the liver, lungs, or peritoneum (the lining of the abdominal cavity), the median survival with treatment is around 13 months, according to Mayo Clinic researchers. “Median” means half of patients live longer and half live shorter than that mark.
That 13-month figure reflects patients receiving standard chemotherapy. Newer combinations of targeted therapy and immunotherapy have pushed progression-free survival to about 10 months in clinical trials, with overall survival reaching roughly 20 months in select groups of patients whose tumors carry specific protein markers. These treatments don’t work for everyone, though. In one major trial, patients whose tumors lacked a particular protein actually did worse when immunotherapy was added to their regimen, highlighting why tumor testing matters before choosing a treatment path.
Where the Cancer Starts Matters
Stomach cancer isn’t one disease. Where in the stomach the tumor forms and what it looks like under a microscope both influence prognosis. Cancers in the upper part of the stomach, near where the esophagus connects (called the cardia), tend to carry a worse prognosis than cancers in the lower portions. Cardia cancers are most common in white males and least common in women of all racial backgrounds.
The cell pattern also matters. Intestinal-type stomach cancers, which form gland-like structures, generally respond better to treatment and carry a somewhat better outlook than diffuse-type cancers, where malignant cells scatter individually through the stomach wall. In one study comparing the two types, patients with the intestinal type survived a median of about 8 months on a targeted therapy compared to roughly 5 months for those with the diffuse type. That said, statistical analysis from the same study suggested the cell type alone wasn’t an independent predictor of survival. Other factors like overall health, tumor size, and response to treatment muddied the picture.
Does Age Change the Outlook?
You might expect younger patients to fare better, but the data is more nuanced. A study comparing patients under 40, those between 41 and 65, and those 66 and older found no statistically significant difference in overall survival between the groups. The median survival across all ages was 16 months. Younger patients may tolerate aggressive treatment better, but they also tend to be diagnosed with more aggressive tumor subtypes, particularly diffuse-type cancers. These opposing forces roughly cancel each other out in the survival statistics.
Long-Term Survival Beyond Five Years
About 15% of adults diagnosed with stomach cancer are alive 10 years later, according to Cancer Research UK data. That number is pulled down considerably by late-stage diagnoses. For people whose cancer was caught early and treated with surgery, the long-term picture is much brighter, with localized cancers offering five-year survival rates near 78%.
The risk of recurrence is highest in the first two to three years after treatment. If you pass the five-year mark without the cancer returning, your odds of continued long-term survival improve substantially, though ongoing monitoring remains important because late recurrences, while uncommon, can still happen.
Factors That Shift Your Individual Outlook
Statistics describe populations, not individuals. Several things can push your prognosis in a better or worse direction:
- Surgical eligibility: If the tumor can be completely removed with clear margins, the survival advantage is significant. Surgery is the only treatment that offers a realistic chance of cure for stomach cancer.
- Tumor biology: Cancers that overproduce certain proteins (like HER2) may respond to targeted therapies that block those proteins. Testing your tumor for these markers helps identify treatment options that might extend survival.
- Overall health: Nutritional status and physical fitness at the time of diagnosis affect how well your body tolerates treatment and recovers from surgery.
- Response to initial treatment: How the tumor responds to the first round of chemotherapy is one of the strongest early signals of longer-term outcomes.
The numbers are improving over time as treatment options expand. The five-year survival rates published today are based on patients diagnosed several years ago, meaning they don’t fully reflect the newest therapies now available. For someone diagnosed today, the real-world outlook may be somewhat better than what current statistics suggest.